Publications by authors named "Xiling Guo"

Claim this Profile
I
Isolation of neutralizing antibodies against SARS-CoV-2 through an epitope-guided negative screening by phage display.
Ming Lu, Yin Chen, Xiaoyu Liu, Fang Gao, Liming Gou, Xiling Guo

J Biomed Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Photonic Crystal Array Enhanced Cellular Force Microscopy for High-Throughput Detection of Regulated Cell Death and Cytopathic Effects.
Yifu Fu, Xiling Guo, Qiwei Li, Jiankang Zhou, Menglin Qiu

ACS Nano· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.
Lairun Jin, Rong Tang, Shipo Wu, Xiling Guo, Haitao Huang

Emerg Microbes Infect· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 6-Month Antibody Durability of Heterologous Convidecia Plus CoronaVac and Homologous CoronaVac Immunizations in People Aged 18-59 Years and over 60 Years Based on Two Randomized Controlled Trials in China.
Hudachuan Jiang, Pengfei Jin, Xiling Guo, Jiahong Zhu, Xue Wang

Vaccines (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials.
Xin Xia, Zhong-Ming Tan, Peng Wan, Hao Zheng, Rong Tang, Xi-Ling Guo

J Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.
Rong Tang, Hui Zheng, Bu-Sen Wang, Jin-Bo Gou, Xi-Ling Guo

Lancet Respir Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.
Yan-Fei Wu, Ming-Wei Wei, Rui-Jie Wang, Xi-Ling Guo, Hong-Xing Pan

Expert Rev Vaccines· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial.
Peng-Fei Jin, Xi-Ling Guo, Jin-Bo Gou, Li-Hua Hou, Zhi-Zhou Song

Lancet Reg Health West Pac· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens.
Hu-Dachuan Jiang, Xi-Ling Guo, Peng-Fei Jin, Rong Tang, Jing-Xin Li

Emerg Microbes Infect· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
Ai-Min Hui, Jingxin Li, Li Zhu, Rong Tang, Huayue Ye, Xiling Guo

Lancet Reg Health West Pac· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
Jing-Xin Li, Shi-Po Wu, Xi-Ling Guo, Rong Tang, Bao-Ying Huang

Lancet Respir Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.
Jingxin Li, Ai-Min Hui, Xiang Zhang, Lei Ge, Yuanzheng Qiu, Xiling Guo

Adv Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
Pengfei Jin, Xiling Guo, Wei Chen, Shihua Ma, Hongxing Pan

PLoS Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Disinfectants Suitable for Inactivating SARS-CoV-2 at Cold-Chain Temperature.
Xiaosong Wu, Yin Chen, Ling Wang, Xiling Guo, Lunbiao Cui

Food Environ Virol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
Jingxin Li, Lihua Hou, Xiling Guo, Pengfei Jin, Shipo Wu

Nat Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
Jia Zou, Li Li, Peiyi Zheng, Wenhua Liang, Siyi Hu, Xiling Guo

J Clin Invest· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Liguo Zhu, Xin Xu, Baoli Zhu, Xiling Guo, Ke Xu

Microbiol Spectr· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.
Yuan Liu, Lianpan Dai, Xiaoli Feng, Ran Gao, Nan Zhang, Xiling Guo

Mol Biomed· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.
Li Zhang, Lei Cao, Xing-Su Gao, Bin-Yang Zheng, Yong-Qiang Deng, Xi-Ling Guo

Natl Sci Rev· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
Fan-Yue Meng, Fan Gao, Si-Yue Jia, Xiang-Hong Wu, Jing-Xin Li, Xi-Ling Guo

Signal Transduct Target Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
Jingxin Li, Aimin Hui, Xiang Zhang, Yumei Yang, Rong Tang, Xiling Guo

Nat Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.
Yiyue Ge, Tingzhong Tian, Suling Huang, Fangping Wan, Jingxin Li, Xiling Guo

Signal Transduct Target Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
Aleksandra Milewska, Ying Chi, Artur Szczepanski, Emilia Barreto-Duran, Agnieszka Dabrowska, Xiling Guo

J Virol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro inactivation of SARS-CoV-2 by commonly used disinfection products and methods.
Guo Xiling, Chen Yin, Wang Ling, Wu Xiaosong, Fan Jingjing

Sci Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China.
Ying Chi, Yiyue Ge, Bin Wu, Wenshuai Zhang, Tao Wu, Xiling Guo

J Infect Dis· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis